►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".
►►Very important notification on publication fee
Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Easy submission via online system
● Efficient and professional peer review
● Rapid pre-print online publication
● No charge for publication and open access
● International visibility-All full texts are free in PubMed Central
Announcements
Publication of the 2nd issue in 2020 |
|
In this issue, advances in the role of ABC transporters, four and a half LIM domains protein 1, and mechanical microenvironment in tumorigenesis and cancer development have been displayed in several reviews. The review written by Prof. Yun Niu focuses on special histological types and emerging therapeutic methods for triple negative breast cancer. Original researches on clinical oncology refer to MRI-guided and targeted theranostics of colorectal cancer, higher recurrence risk after microwave ablation in hepatocellular carcinoma patients with cholecystectomy, related studies on advanced non-small cell lung cancer and osteogenic sarcoma, and so on. Application of cancer nano-technology and the roles of some molecules and signaling pathways in cancer progression have also been included. Just as before, we hope the fruitful contents in this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.
|
|
| Posted: 2020-05-18 | |
Publication of the 1st issue in 2020 |
|
The two editorials are both related to precision oncology. Professor Yu and Wei comment on the Human Pan-genome Analysis system (HUPAN) which could be used in determining differences between individual genomes and whether these differences are related to cancer susceptibility. Another editorial contributed by Professor Zhang and You focuses on CRISPR-Cas13a system that has been found to effectively inhibit tumor growth and angiogenesis in an intracranial glioma model. Reviews and original articles in this issue revealed that some molecules such as N6-methyladenosine, COX-2, CDK11, play important roles in tumorigenesis and development of cancer. Besides, other clinical research reported new findings in diagnosis and treatment for gastric cancer, esophageal cancer, nasopharyngeal carcinoma, and ovarian cancer. We hope the content of this issue will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.
|
|
| Posted: 2020-02-14 | |
| More Announcements... |
Vol 17, No 2: May 2020
Table of Contents
Review
| ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance | |
| Wanjiru Muriithi, Lucy Wanjiku Macharia, Carlos Pilotto Heming, et al. | 253-269 |
| Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression | |
| Xiaofan Wei, Hongquan Zhang | 270-281 |
| Role of the mechanical microenvironment in cancer development and progression | |
| Qiuping Liu, Qing Luo, Yang Ju, et al. | 282-292 |
| Triple negative breast cancer: special histological types and emerging therapeutic methods | |
| Lu Cao, Yun Niu | 293-306 |
| Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer | |
| Yanan Li, Jingqi Xin, Yongbing Sun, et al. | 307-327 |
Original Article
| CDK11 negatively regulates Wnt/β-catenin signaling in the endosomal compartment by affecting microtubule stability | |
| Danmin Ou, Lin Chen, Jiang He, et al. | 328-342 |
| Heat shock protein 47 promotes tumor survival and therapy resistance by modulating AKT signaling via PHLPP1 in colorectal cancer | |
| Yijye Chern, Peter Zhang, Hyelim Ju, et al. | 343-356 |
| CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma | |
| Ting Li, Si Wu, Lei Jia, et al. | 357-370 |
| KIF18B promotes tumor progression in osteosarcoma by activating β-catenin | |
| Tian Gao, Ling Yu, Zhiwei Fang, et al. | 371-386 |
| DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors | |
| Yangling Li, Dongmei Zhou, Shuang Xu, et al. | 387-400 |
| Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development | |
| Qi Wang, Qin Tang, Lijun Zhao, et al. | 401-417 |
| Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling | |
| Xiaoling Zhang, Yan Zhang, Yanan Jia, et al. | 418-432 |
| Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab | |
| Chao Yang, Yanli Tan, Hongzhao Qi, et al. | 433-443 |
| Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer | |
| Juan Moreno-Rubio, Santiago Ponce, Rosa Álvarez, et al. | 444-457 |
| Identification of novel Lynch syndrome mutations in Chinese patients with endometriod endometrial cancer | |
| Caixia Ren, Yan Liu, Yuxiang Wang, et al. | 458-467 |
| Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors | |
| Lei Zhu, Xiaofeng Li,, Jian Wang, et al | 468-477 |
| Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis | |
| Hongcai Yang, Yi Yang, Jianping Dou, et al. | 478-491 |
| Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications | |
| Xiaofei Zhu, Di Chen, Yangsen Cao, et al. | 492-500 |
| Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy | |
| Zhichao Liao, Ting Li, Chao Zhang, et al | 501-512 |
Erratum
| Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients | |
| Xingsheng Hu, Dongyong Yang, Yalun Li, et al. | 513 |
OUR FRIENDS
